To include your compound in the COVID-19 Resource Center, submit it here.

Sol-Gel reports Phase II data for Epsolay in rosacea

In February, Sol-Gel Technologies Ltd. (NASDAQ:SLGL) said once-daily Epsolay (formerly VERED) met the co-primary endpoints in a Phase II trial

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE